Institutional Investors Control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Were Rewarded Last Week After Stock Increased 4.9%
BioCryst Pharmaceuticals Insiders Added US$1.05m Of Stock To Their Holdings
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
New York Manufacturing Hits Low, Inflation Fears Rise
Express News | BioCryst Pharmaceuticals Inc - Seeks to Block FDA Approval of Generic Orladeyo Until Patent Expiration
Executive Reshuffles: SBUX, KR, and LVS
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Falls 8% Following CFO Departure Announcement
Express News | BioCryst Pharmaceuticals Inc - CFO Anthony Doyle to Resign Effective April 9, 2025
JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $18
Analysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its Yearly Results
Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $12
BioCryst Pharmaceuticals | 10-K: FY2024 Annual Report
Citizens Capital Markets Reiterates Market Outperform on BioCryst Pharma, Maintains $18 Price Target
Breakeven On The Horizon For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Jefferies Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $12
BioCryst Pharmaceuticals Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $10 to $30
BioCryst Pharma Analyst Ratings
RBC Capital Adjusts Price Target on BioCryst Pharmaceuticals to $11 From $10, Keeps Outperform Rating
Unlock the Full List